Logo

Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

Share this
Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

Shots:

  • The US FDA has cleared an IND application to initiate P-Ib/II (SHIELD-2) to evaluate the safety, tolerability & preliminary efficacy of elzovantinib (MET inhibitor) + EQRx’s aumolertinib in patients with EGFR mutant MET-amplified NSCLC. The trial is expected to initiate in mid-2022
  • In preclinical data, the combination therapy has the potential to increase anti-tumor activity based on complementary mechanisms while 15 to 20% has developed MET amplification who progress on a 1L EGFR inhibitor develop MET amplification based on acquired resistance
  • Aumolertinib is an EGFR inhibitor & was approved in China for 1L treatment of EGFR mutant NSCLC & 2L treatment of T790M+ EGFR mutant NSCLC

Ref: Globe Newswire | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions